Ironwood Pharmaceuticals amended its credit agreement to increase its revolving credit facility from $500 million to $550 million and extended its maturity date to December 31, 2028, while also adjusting leverage ratios. Additionally, the company dec
AI Assistant
IRONWOOD PHARMACEUTICALS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.